Tizona Therapeutics is a US immuno-oncology company. Abbvie purchased an option to in-license Tizona’s most advanced clinical program in 2019 for a total potential deal value > $1b which has now been spun-out into a newco. Gilead purchased an option to acquire the remainder of Tizona in 2020 with $300m upfront and total potential deal value > $1.5b

LocationSouth San Francisco, CA
CEOChristine O'Brien
Partner Kurt von Emster